Table 3

Association between investigated SNPs and clinical outcome

ParameterTest variablesHR (95% CI)P value
Univariate analysis (PFS)
IFNG c.874T>AAA+AT vs TT0.76 (0.58 to 0.99)0.045
IL2RA c.64+5006T>CCC+CT vs TT0.80 (0.62 to 1.04)0.098
 WHO performance status0 vs ≥10.66 (0.46 to 0.95)0.027
 SexMale vs female1.38 (1.06 to 1.80)0.018
Multivariate analysis (PFS)
IFNG c.874T>AAA+AT vs TT0.79 (0.58 to 1.07)0.131
 WHO performance status0 vs ≥10.66 (0.45 to 0.95)0.024
 SexMale vs female1.26 (0.92 to 1.71)0.148
­­­­
IL2RA c.64+5006T>CCC+CT vs TT0.81 (0.60 to 1.10)0.177
 WHO performance status0 vs ≥10.65 (0.45 to 0.93)0.019
­­­­
 SexMale vs female1.29 (0.95 to 1.76)0.101
IFNG c.874T>AAA+AT vs TT0.76 (0.55 to 1.05)0.093
 WHO performance status0 vs ≥10.52 (0.34 to 0.77)0.001
 SexMale vs female1.45 (1.03 to 2.02)0.32
Univariate analysis (OS)
IFNG c.874T>AAA+AT vs TT0.72 (0.55 to 0.95)0.021
 WHO PS0 vs ≥10.52 (0.35 to 0.77)0.001
 SexMale vs female1.40 (1.05 to 1.86)0.023
Multivariate analysis (OS)
IFNG c.874T>AAA+AT vs TT0.76 (0.55 to 1.05)0.093
 WHO performance status0 vs ≥10.52 (0.34 to 0.77)0.001
 SexMale vs female1.45 (1.03 to 2.02)0.32
ParameterTest variablesOR (95% CI)P value
Univariate analysis (BOR)
IL10 c.387+284C>AAA vs AA +AC0.25 (0.07 to 0.89)0.033
ZAP70 −21–4127C>AAA vs CC+AC0.50 (0.25 to 0.98)0.045
 Primary tumorOther vs adeno0.63 (0.40 to 0.98)0.041
Multivariate analysis (BOR)
IL10 c.387+284C>AAA vs AA +AC0.24 (0.07 to 0.84)0.026
 Primary tumorOther vs adeno0.61 (0.39 to 0.96)0.031
­­­­
ZAP70 −21–4127C>AAA vs CC+AC0.49 (0.24 to 0.97)0.042
 Primary tumorOther vs adeno0.61 (0.39 to 0.96)0.033
  • Univariate and multivariate analysis of the association between germline SNPs (except those related to GZMB variation; those are shown in table 2) and PFS, OS, or BOR. Only SNPs that were associated with OS/PFS/BOR (p value <0.1) are shown and included in the multivariate analysis. Significance is marked by *.

  • BOR, best overall response; OS, overall survival; PFS, progression-free survival; SNPs, single-nucleotide polymorphisms; WHO PS, WHO performance status.